Crossmark

The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial

Crossref DOI link: https://doi.org/10.1007/s00210-024-03705-4

Published Online: 2024-12-16

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Sheng-ting

Tan, Hong-yi

Yang, Shuang

Yang, Xiao-yan

Cui, Chang

Huang, Jie

Yang, Guo-ping
Funding

Funding for this research was provided by:

Hunan Provincial Natural Science Foundation of China (No. 2023JJ60513, No. 2023JJ60513, No. 2023JJ60513, No. 2023JJ60513, No. 2023JJ60513, No. 2023JJ60513, No. 2023JJ60513)

Shanghai Hengrui Biotech, Inc.
License Information

Text and Data Mining valid from 2024-12-16

Version of Record valid from 2024-12-16
More Information

Article History

Received: 28 September 2024

Accepted: 3 December 2024

First Online: 16 December 2024

Declarations

: This study investigated the safety and tolerability of SHR6508 in healthy Chinese subjects and the pharmacokinetic characteristics and pharmacodynamics of SHR6508 in healthy subjects. This study provides evidence for subsequent clinical studies of SHR6508 and may provide a new option for the treatment of SHPT. This study is available as a preprint at .

: The authors declare no competing interests.

Document is current

Any future updates will be listed below